Muscimol

GABA agonist therapy in schizophrenia

C. A. Tamminga, J. W. Crayton, T. N. Chase

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Muscimol (3-hydroxy-5-aminomethylisoxazole), originally isolated from 'Amanita muscaria', is the structural analogue of GABA. Muscimol was administered to six patients in a double-blind, placebo-controlled design. All subjects were diagnosed as having chronic schizophrenia. During high-dose muscimol treatment, all study subjects evidenced diffuse myoclonic twitching or somnolence, and many experienced vivid dreams, dizziness, and confusion. At dose levels below 5 mg, many patients experienced a tranquilizing effect from muscimol. These subjects, when receiving the active drug, reported feeling more relaxed and less anxious and claimed a positive drug experience, despite their lack of relief from psychotic thinking. No significant change in vital signs or routine laboratory studies occurred.

Original languageEnglish (US)
Pages (from-to)746-747
Number of pages2
JournalAmerican Journal of Psychiatry
Volume135
Issue number6
StatePublished - 1978

Fingerprint

GABA Agonists
Muscimol
Schizophrenia
Tranquilizing Agents
Amanita
Confusion
Vital Signs
Dizziness
Therapeutics
Pharmaceutical Preparations
gamma-Aminobutyric Acid
Emotions
Placebos

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Tamminga, C. A., Crayton, J. W., & Chase, T. N. (1978). Muscimol: GABA agonist therapy in schizophrenia. American Journal of Psychiatry, 135(6), 746-747.

Muscimol : GABA agonist therapy in schizophrenia. / Tamminga, C. A.; Crayton, J. W.; Chase, T. N.

In: American Journal of Psychiatry, Vol. 135, No. 6, 1978, p. 746-747.

Research output: Contribution to journalArticle

Tamminga, CA, Crayton, JW & Chase, TN 1978, 'Muscimol: GABA agonist therapy in schizophrenia', American Journal of Psychiatry, vol. 135, no. 6, pp. 746-747.
Tamminga, C. A. ; Crayton, J. W. ; Chase, T. N. / Muscimol : GABA agonist therapy in schizophrenia. In: American Journal of Psychiatry. 1978 ; Vol. 135, No. 6. pp. 746-747.
@article{3599af0a3f314eb0afb9c9af12ba1a94,
title = "Muscimol: GABA agonist therapy in schizophrenia",
abstract = "Muscimol (3-hydroxy-5-aminomethylisoxazole), originally isolated from 'Amanita muscaria', is the structural analogue of GABA. Muscimol was administered to six patients in a double-blind, placebo-controlled design. All subjects were diagnosed as having chronic schizophrenia. During high-dose muscimol treatment, all study subjects evidenced diffuse myoclonic twitching or somnolence, and many experienced vivid dreams, dizziness, and confusion. At dose levels below 5 mg, many patients experienced a tranquilizing effect from muscimol. These subjects, when receiving the active drug, reported feeling more relaxed and less anxious and claimed a positive drug experience, despite their lack of relief from psychotic thinking. No significant change in vital signs or routine laboratory studies occurred.",
author = "Tamminga, {C. A.} and Crayton, {J. W.} and Chase, {T. N.}",
year = "1978",
language = "English (US)",
volume = "135",
pages = "746--747",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "6",

}

TY - JOUR

T1 - Muscimol

T2 - GABA agonist therapy in schizophrenia

AU - Tamminga, C. A.

AU - Crayton, J. W.

AU - Chase, T. N.

PY - 1978

Y1 - 1978

N2 - Muscimol (3-hydroxy-5-aminomethylisoxazole), originally isolated from 'Amanita muscaria', is the structural analogue of GABA. Muscimol was administered to six patients in a double-blind, placebo-controlled design. All subjects were diagnosed as having chronic schizophrenia. During high-dose muscimol treatment, all study subjects evidenced diffuse myoclonic twitching or somnolence, and many experienced vivid dreams, dizziness, and confusion. At dose levels below 5 mg, many patients experienced a tranquilizing effect from muscimol. These subjects, when receiving the active drug, reported feeling more relaxed and less anxious and claimed a positive drug experience, despite their lack of relief from psychotic thinking. No significant change in vital signs or routine laboratory studies occurred.

AB - Muscimol (3-hydroxy-5-aminomethylisoxazole), originally isolated from 'Amanita muscaria', is the structural analogue of GABA. Muscimol was administered to six patients in a double-blind, placebo-controlled design. All subjects were diagnosed as having chronic schizophrenia. During high-dose muscimol treatment, all study subjects evidenced diffuse myoclonic twitching or somnolence, and many experienced vivid dreams, dizziness, and confusion. At dose levels below 5 mg, many patients experienced a tranquilizing effect from muscimol. These subjects, when receiving the active drug, reported feeling more relaxed and less anxious and claimed a positive drug experience, despite their lack of relief from psychotic thinking. No significant change in vital signs or routine laboratory studies occurred.

UR - http://www.scopus.com/inward/record.url?scp=0018140403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018140403&partnerID=8YFLogxK

M3 - Article

VL - 135

SP - 746

EP - 747

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 6

ER -